Lipids in cystic fibrosis

Expert Review of Respiratory Medicine

Volumn 5, Issue 4, 2011, Pages 527-535

  Becker, Katrin Anne ^a   Henry, Brian ^a   Ziobro, Regan ^a   Riethmüller, Joachim ^b   Gulbins, Erich ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

amitripyline; ceramide; Cftr; cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

15 KETO PROSTAGLANDIN 2; AMITRIPTYLINE; AMLODIPINE; CERAMIDE; CHLORPROTHIXENE; CYTOKINE; DESIPRAMINE; FLUOXETINE; LIPID; PROSTAGLANDIN; SERTRALINE; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; TRIMIPRAMINE; UNCLASSIFIED DRUG;

BURKHOLDERIA CEPACIA; CAVEOLA; CYSTIC FIBROSIS; DISEASE PREDISPOSITION; EXPERIMENTAL MODEL; GASTROINTESTINAL DISEASE; HAEMOPHILUS INFLUENZAE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; LIPID RAFT; LUNG FIBROSIS; LUNG INFECTION; MOLECULAR MECHANICS; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 80052625342     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.36     Document Type: Review

References (108)

1. Kerem B, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245, 1073-1080 (1989). (Pubitemid 19231815)
2. Rommens JM, Iannuzzi MC, Kerem B et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245, 1059-1065 (1989). (Pubitemid 19231813)
3. Snouwaert JN, Brigman KK, Latour AM et al. An animal model for cystic fibrosis made by gene targeting. Science 257, 1083-1088 (1992).
4. Ratcliff R, Evans MJ, Cuthbert AW et al. Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat. Genet. 4, 35-41 (1993). (Pubitemid 23165909)
5. Dorin JR, Dickinson P, Emslie E et al. Successful targeting of the mouse cystic fibrosis transmembrane conductance regulator gene in embryonal stem cells. Transgenic Res. 1, 101-105 (1992).
6. Larbig M, Jansen S, Dorsch M et al. Residual cftr expression varies withage in cftr(tm1Hgu) cystic fibrosis mice: impact on morphology and physiology. Pathobiology 70, 89-97 (2002). (Pubitemid 36002568)
7. Gray MA, Winpenny JP, Porteous DJ, Dorin JR, Argent BE. CFTR and calcium-activated chloride currents in pancreatic duct cells of a transgenic CF mouse. Am. J. Physiol. 266, C213-C221 (1994).
8. Colledge WH, Abella BS, Southern KW et al. Generation and characterization of a delta F508 cystic fibrosis mouse model. Nat. Genet. 10, 445-452 (1995).
9. Zeiher BG, Eichwald E, Zabner J et al. A mouse model for the delta F508 allele of cystic fibrosis. J. Clin. Invest. 96, 2051-2064 (1995).
10. Delaney SJ, Alton EW, Smith SN et al. Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO J. 15, 955-963 (1996). (Pubitemid 26077823)
11. Dickinson P, Smith SN, Webb S et al. The severe G480C cystic fibrosis mutation, when replicated in the mouse, demonstrates mistrafficking, normal survival and organ-specific bioelectrics. Hum. Mol. Genet. 11, 243-251 (2002). (Pubitemid 34173353)
12. Kent G, Iles R, Bear CE et al. Lung disease in mice with cystic fibrosis. J. Clin. Invest. 100, 3060-3069 (1997). (Pubitemid 28022844)
13. Kent G, Oliver M, Foskett JK et al. Phenotypic abnormalities in long-term surviving cystic fibrosis mice. Pediatr. Res. 40, 233-241 (1996). (Pubitemid 26249675)
14. Durie PR, Kent G, Phillips MJ, Ackerley CA. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am. J. Pathol. 164, 1481-1493 (2004). (Pubitemid 38387813)
15. Hodges CA, Cotton CU, Palmert MR, Drumm ML. Generation of a conditional null allele for Cftr in mice. Genesis 46, 546-552 (2008).
16. Sun X, Sui H, Fisher JT et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J. Clin. Invest. 120, 3149-3160 (2010).
17. Chen J.H, Stoltz, DA, Karp PH et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 143, 911-923 (2010).
18. Meyerholz DK, Stoltz DA, Pezzulo AA, Welsh MJ. Pathology of gastrointestinal organs in a porcine model of cystic fibrosis. Am. J. Pathol. 176, 1377-1389 (2010).
19. Meyerholz DK, Stoltz DA, Namati E et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am. J. Respir. Crit. Med. 182, 1251-1261 (2010).
20. Stoltz DA, Meyerhold DK, Pezzulo et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci. Trans. Med. 2, 29ra31 (2010).
21. Verhaeghe C, Delbecque K, de Leval L, Oury C, Bours V. Early inflammation in the airways of a cystic fibrosis foetus. J. Cyst. Fibros. 6, 304-308 (2007). (Pubitemid 46971896)
22. Khan TZ, Wagener JS, Bost T et al. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151, 1075-1082 (1995).
23. Tabary O, Escotte S, Couetil JP et al. Relationship between IkBa deficiency, NFkB activity and interleukin-8 production in CF human airway epithelial cells. Pflugers Arch. 443(Suppl. 1), S40-S44 (2001). (Pubitemid 33086950)
24. Tirouvanziam R, de Bentzmann S, Hubeau C et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am. J. Respir. Cell Mol. Biol. 23, 121-127 (2000). (Pubitemid 30656417)
25. Inoue H, Massion PP, Ueki IF et al. Pseudomonas stimulates interleukin-8 mRNA expression selectively in airway epithelium, in gland ducts, and in recruited neutrophils. Am. J. Respir. Cell Mol. Biol. 11, 651-663 (1994).
26. Oceandy D, McMorran BJ, Smith SN et al. Gene complementation of airway epithelium in the cystic fibrosis mouse is necessary and sufficient to correct the pathogen clearance and inflammatory abnormalities. Hum. Mol. Genet. 11, 1059-1067 (2002). (Pubitemid 34521087)
27. Bonfield TL, Konstan MW, Burfeind P et al. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 13, 257-261 (1995).
28. Venkatakrishnan A, Stecenko AA, King G et al. Exaggerated activation of nuclear factor-kappaB and altered IkB-b processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 23, 396-403 (2000).
29. Griese M, Essl R, Schmidt R et al. Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 170, 1000-1005 (2004). (Pubitemid 39425697)
30. Schultz MJ, Rijneveld AW, Florquin S et al. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L285-L290 (2002). (Pubitemid 34654680)
31. Goldstein W, Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and protease inhibitors in patients with cystic fibrosis. Am. Rev. Respir. Dis. 134, 49-56 (1986). (Pubitemid 16057459)
32. Matsui H, Verghese MW, Kesimer M et al. Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J. Immunol. 175, 1090-1099 (2005). (Pubitemid 41094995)
33. Matsui H, Wagner VE, Hill DB et al. A physical linkage between CF airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc. Natl Acad. Sci. USA 103, 18131-18136 (2006). (Pubitemid 44871624)
34. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 295, 1487 (2002). (Pubitemid 34173996)
35. Worlitzsch D, Tarran R, Ulrich M et al. Reduced oxygen concentrations in airway mucus contribute to the early and late pathogenesis of Pseudomonas aeruginosa CF airways infection. J. Clin. Invest. 109, 317-325 (2002).
36. Pier GB, Grout M, Zaidi TS et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271, 64-67 (1996). (Pubitemid 26033276)
37. Coleman FT, Mueschenborn S, Meluleni G et al. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc. Natl Acad. Sci. USA 100, 1949-1954 (2003). (Pubitemid 36254554)
38. Schroeder TH, Reiniger N, Meluleni G et al. Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. J. Immunol. 166, 7410-7418 (2001). (Pubitemid 32525618)
39. Muenzner P, Bachmann V, Zimmermann W, Hentschel J, Hauck CR. Human-restricted bacterial pathogens block shedding of epithelial cells by stimulating integrin activation. Science 329, 1197-1201 (2010).
40. Grassmè H, Kirschnek S, Riethmüeller J et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 290, 527-530 (2000).
41. Jendrossek V, Fillon S, Belka C et al. Apoptotic response of Chang cells to infection with Pseudomonas aeruginosa strains PAK and PAO-I: molecular ordering of the apoptosis signaling cascade and role of type IV pili. Infect. Immun. 71, 2665-2673 (2003). (Pubitemid 36519882)
42. Grassmè H, Jendrossek V, Riehle A et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 9, 322-330 (2003). (Pubitemid 36362788)
43. Cannon CL, Kowalski MP, Stopak KS, Pier GB. Pseudomonas aeruginosa-induced apoptosis is defective in respiratory epithelial cells expressing mutant cystic fibrosis transmembrane conductance regulator. Am. J. Resp. Cell Mol. Biol. 29, 188-197 (2003). (Pubitemid 36936646)
44. Fadok VA, Bratton DL, Konowal A et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/ paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101, 890-898 (1998). (Pubitemid 28096086)
45. Sekine C, Yagita H, Kobata T et al. Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32- mediated apoptosis. Biochem. Biophys. Res. Commun. 228, 14-20 (1996). (Pubitemid 26390625)
46. Kumar V, Becker T, Jansen S et al. Expression levels of FAS are regulated through an evolutionary conserved element in intron 2, which modulates cystic fibrosis disease severity. Genes Immun. 9, 689-696 (2008).
47. Di A, Brown ME, Deriy LV et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 8, 933-944 (2006). (Pubitemid 44314724)
48. Barasch J, Kiss B, Prince A et al. Defective acidification of intracellular organelles in cystic fibrosis. Nature 352, 70-73 (1991). (Pubitemid 21896700)
49. Haggie PM, Verkman AS. Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J. Biol. Chem. 282, 31422-31428 (2007). (Pubitemid 350044877)
50. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu. Rev. Cell Dev. Biol. 14, 111-136 (1998). (Pubitemid 29001451)
51. Kolesnick RN, Goni FM, Alonso A. Compartmentalization of ceramide signaling: physical foundations and biological effects. J. Cell Physiol. 184, 285-300 (2000). (Pubitemid 30625491)
52. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 387, 569-572 (1997). (Pubitemid 27248754)
53. Eggeling C, Ringemann C, Medda R et al. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 457, 1159-1162 (2009).
54. Grassmè H, Jekle A, Riehle A et al. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276, 20589-20596 (2001).
55. Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Oncogene 22, 7070-7077 (2003). (Pubitemid 37386676)
56. Grassmè H, Gulbins E, Brenner B et al. Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell 91, 605-615 (1997). (Pubitemid 27513652)
57. Hauck CR, Grassmè H, Bock J et al. Acid sphingomyelinase is involved in CEACAM receptor-mediated phagocytosis of Neisseria gonorrhoeae. FEBS Lett. 478, 260-266 (2000). (Pubitemid 30621628)
58. Cremesti A, Paris F, Grassmè H et al. Ceramide enables fas to cap and kill. J. Biol. Chem. 276, 23954-23961 (2001). (Pubitemid 37410795)
59. Grassmè H, Schwarz H, Gulbins E. Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem. Biophys. Res. Commun. 284, 1016-1030 (2001). (Pubitemid 32924751)
60. Grassmè H, Jendrossek V, Bock J, Riehle A, Gulbins E. Ceramide-rich membrane rafts mediate CD40 clustering. J. Immunol. 168, 298-307 (2002). (Pubitemid 34014130)
61. Dumitru CA, Gulbins E. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis. Oncogene 25, 5612-5625 (2006). (Pubitemid 44387617)
62. Abdel Shakor AB, Kwiatkowska K, Sobota A. Cell surface ceramide generation precedes and controls FcgRII clustering and phosphorylation in rafts. J. Biol. Chem. 279, 36778-36787 (2004). (Pubitemid 39129026)
63. Goggel R, Winoto-Morbach S, Vielhaber G et al. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat. Med. 10, 155-160 (2004). (Pubitemid 38524885)
64. Grassmè H, Riehle A, Wilker B, Gulbins E. Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. J. Biol. Chem. 280, 26256-26262 (2005). (Pubitemid 41022223)
65. Rotolo JA, Zhang J, Donepudi M et al. Caspase-dependent and -independent activation of acid sphingomyelinase signaling. J. Biol. Chem. 280, 26425-26434 (2005). (Pubitemid 41022239)
66. Lacour S, Hammann A, Grazide S et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 64, 3593-3598 (2004). (Pubitemid 38657937)
67. Heinrich M, Wickel M, Schneider-Brachert W et al. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. Embo. J. 18, 5252-5263 (1999). (Pubitemid 29465576)
68. 2 and facilitates its membrane docking and arachidonic acid release. FASEB J. 15, 7-9 (2001).
69. Zhang Y, Yao B, Delikat S et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 89, 63-72 (1997). (Pubitemid 27180586)
70. Dobrowsky RT, Hannun YA. Ceramide-activated protein phosphatase: partial purification and relationship to protein phosphatase 2A. Adv. Lipid Res. 25, 91-104 (1993).
71. Muller G, Ayoub M, Storz P et al. PKC zeta is a molecular switch in signal transduction of TNF-α, bifunctionally regulated by ceramide and arachidonic acid. EMBO J. 14, 1961-1969 (1995).
72. Huwiler A, Fabbro D, Pfeilschifter J. Selective ceramide binding to protein kinase C-alpha; and -d isoenzymes in renal mesangial cells. Biochemistry 37, 14556-14562 (1998). (Pubitemid 28489064)
73. + channel in T lymphocytes upon Fas stimulation. J. Biol. Chem. 271, 20465-20469 (1996). (Pubitemid 26281818)
74. Gulbins E, Szabo I, Baltzer K, Lang F. Ceramide-induced inhibition of T lymphocyte voltage-gated potassium channel is mediated by tyrosine kinases. Proc. Natl Acad. Sci. USA 94, 7661-7666 (1997). (Pubitemid 27345373)
75. Lepple-Wienhues A, Belka C, Laun T et al. Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proc. Natl Acad. Sci. USA 96, 13795-13800 (1999).
76. Bock J, Szabo I, Gamper N, Adams C, Gulbins E. Ceramide inhibits the potassium channel Kv1.3 by the formation of membrane platforms. Biochem. Biophys. Res. Commun. 305, 890-897 (2003). (Pubitemid 36597847)
77. Avota E, Gulbins E, Schneider-Schaulies S. Ceramide generation is essential for enhancement of viral uptake in dendretic cells. PLoS Pathog. 7(2), e1001290 (2011).
78. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9, 139-150 (2008). (Pubitemid 351158911)
79. Okino N, He X, Gatt S et al. The reverse activity of human acid ceramidase. J. Biol. Chem. 278, 29948-29953 (2003). (Pubitemid 36962383)
80. Ishibashi Y, Nakasone T, Kiyohara M et al. A novel endoglycoceramidase hydrolyzes oligogalactosylceramides to produce galactooligosaccharides and ceramides. J. Biol. Chem. 282, 11386-11396 (2007). (Pubitemid 47100775)
81. Zhang Y, Li X, Carpinteiro A, Gulbins E. Acid sphingomyelinase amplifies redox signaling in Pseudomonas aeruginosa-induced macrophage apoptosis. J. Immunol. 181, 4247-4254 (2008).
82. Zhang Y, Li X, Carpinteiro A et al. Kinase suppressor of Ras-1 protects against pulmonary Pseudomonas aeruginosa infections. Nat. Med. 17(3), 341-346 (2011).
83. Yu H, Zeidan YH, Wu BX et al. Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 41, 367-375 (2009).
84. Perrotta C, Bizzozero L, Cazzato D et al. Syntaxin 4 is required for acid sphingomyelinase activity and apoptotic function. J. Biol. Chem. 285, 40240-40251 (2010).
85. Edelmann B, Bertsch U, Tchikov V et al. Caspase-8 and caspase-7 sequentially mediate proteolytic activation of acid sphingomyelinase in TNF-R1 receptosomes. EMBO J. 30, 379-394 (2011).
86. Qiu H, Edmunds T, Baker-Malcolm J et al. Activation of human acid sphingomyelinase through modification or deletion of C-terminal cysteine. J. Biol. Chem. 278, 32744-32752 (2003). (Pubitemid 37055714)
87. Zhang AY, Yi F, Jin S et al. Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells. Antioxid. Redox Signal. 9, 817-828 (2007).
88. Teichgraber V, Ulrich M, Endlich N et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 14, 382-391 (2008). (Pubitemid 351499396)
89. Kowalski MP, Pier GB. Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for Pseudomonas aeruginosa-induced cellular activation. J. Immunol. 172, 418-425 (2004). (Pubitemid 38020496)
90. Gadjeva M, Paradis-Bleau C, Priebe GP, Fichorova R, Pier GB. Caveolin-1 modifies the immunity to Pseudomonas aeruginosa. J. Immunol. 184, 296-302 (2010).
91. Zaas DW, Duncan MJ, Li G, Wright JR, Abraham SN. Pseudomonas invasion of type I pneumocytes is dependent on the expression and phosphorylation of caveolin-2. J. Biol. Chem. 280, 4864-4872 (2005). (Pubitemid 40288660)
92. Bajmoczi M, Gadjeva M, Alper SL, Pier GB, Golan DE. Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa. Am. J. Physiol. Cell Physiol. 297, C263-C277 (2009).
93. Chidlow JH Jr, Sessa WC. Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation. Cardiovasc. Res. 86, 219-225 (2010).
94. Becker KA, Riethmuller J, Luth A et al. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 42, 716-724 (2010).
95. Becker KA, Tummler B, Gulbins E, Grassmè H. Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death. Biochem. Biophys. Res. Commun. 403, 368-374 (2010).
96. Ulrich M, Worlitzsch D, Viglio S et al. Alveolar inflammation in cystic fibrosis. J. Cyst. Fibros. 9, 217-227 (2010).
97. Zhang Y, Li X, Grassmè H, Doring G, Gulbins E. Alterations in ceramide concentration and pH determine the release of reactive oxygen species by Cftr-deficient macrophages on infection. J. Immunol. 184, 5104-5111 (2009).
98. Brodlie M, McKean MC, Johnson GE et al. Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 182, 369-375 (2010).
99. Bodas M, Min T, Mazur S, Vij N. Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema. J. Immunol. 186, 602-613 (2010).
100. Guilbault C, De Sanctis JB, Wojewodka G et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 38, 47-56 (2008).
101. Cottart CH, Bonvin E, Rey C et al. Impact of nutrition on phenotype in Cftr-deficient mice. Pediatr. Res. 62, 528-532 (2007). (Pubitemid 351338984)
102. Borowitz D, Durie PR, Clarke LL et al. Gastrointestinal outcomes and confounders in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 41, 273-285 (2005). (Pubitemid 41285817)
103. Harmon GS, Dumlao DS, Ng DT et al. Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice. Nat. Med. 16, 313-318 (2010).
104. Perez A, van Heeckeren AM, Nichols D et al. Peroxisome proliferator-activated receptor-g in cystic fibrosis lung epithelium. Am. J. Physiol. Lung Cell Mol. Physiol. 295, L303-L313 (2008).
105. Kornhuber J, Tripal P, Reichel M et al. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J. Med. Chem. 51, 219-237 (2008).
106. Hurwitz R, Ferlinz K, Sandhoff K. The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol. Chem. Hoppe Seyler 375, 447-450 (1994). (Pubitemid 2120332)
107. Roth AG, Drescher D, Yang Y et al. Potent and selective inhibition of acid sphingomyelinase by bisphosphonates. Angew Chem. Int. Ed. Engl. 48, 7560-7563 (2009).
108. Riethmuller J, Anthonysamy J, Serra E et al. Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol. Biochem. 24, 65-72 (2009).